GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (NAS:FTRE) » Definitions » YoY EPS Growth

Fortrea Holdings (Fortrea Holdings) YoY EPS Growth : -784.62% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Fortrea Holdings's YoY EPS Growth for the quarter that ended in Mar. 2024 was -784.62%.

Fortrea Holdings's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-1.15.

Fortrea Holdings YoY EPS Growth Historical Data

The historical data trend for Fortrea Holdings's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings YoY EPS Growth Chart

Fortrea Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
- 127.30 96.75 -101.83

Fortrea Holdings Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -135.33 -57.39 -121.87 -208.47 -784.62

Fortrea Holdings YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Fortrea Holdings's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-0.04-2.182)/ | 2.182 |
=-101.83 %

Fortrea Holdings's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EPS Growth (Q: Mar. 2024 )
=(Earnings per Share (Diluted) (Q: Mar. 2024 )-Earnings per Share (Diluted) (Q: Mar. 2023 )) / | Earnings per Share (Diluted) (Q: Mar. 2023 )) |
=(-1.15--0.13)/ | -0.13 |
=-784.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortrea Holdings YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortrea Holdings (Fortrea Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (NAS:FTRE) » Definitions » YoY EPS Growth
Comparable Companies
ZLAB MLTX DNLI BHVN MDGL NTLA ARWR RVMD IBRX DNA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
K67:Germany
Address
8 Moore Drive, Durham, NC, USA, 27709
Website
https://www.fortrea.com
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Executives
Thomas Pike officer: Chief Executive Officer C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Peter M Neupert director 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Betty D Larson director GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE, CHICAGO IL 60661
R Andrew Eckert director THREE RAVINIA DRIVE, ATLANTA GA 30346
Edward A Pesicka director 9120 LOCKWOOD BLVD, MECHANICSVILLE VA 23116
Amrit Ray director 60 LEVERONI COURT, NOVATO CA 94949
Amanda M. Warren officer: Chief Accounting Officer 8 MOORE DRIVE, DURHAM NC 27703
David Ross Smith director 251 BALLARDVALE STREET, WILMINGTON MA 01887
Van Der Vaart Sandra D director, officer: President and Secretary 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg director, officer: Executive Vice President P O BOX 1017, CHARLOTTE NC 28201-1017
James S. Hanson officer: General Counsel 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Laboratory Corp Of America Holdings 10 percent owner 358 S MAIN ST, BURLINGTON NC 27215
Jill G. Mcconnell officer: Chief Financial Officer 8 MOORE DRIVE, DURHAM NC 27703
Mark A. Morais officer: Chief Operating Officer 8 MOORE DRIVE, DURHAM NC 27703
Robert S. Pringle officer: Treasurer 531 SOUTH SPRING STREET, BURLINGTON NC 27215